依达拉奉对真实世界急性缺血性卒中患者神经症状的影响
基于日本卒中数据库61 048例急性缺血性卒中患者,按卒中亚型分层分析依达拉奉使用与神经症状改善的关系。经多因素校正后,各亚型依达拉奉组NIHSS评分改善均优于未使用组,但差异小于1分,临床意义有限。
要点
- 各缺血性卒中亚型中,依达拉奉组住院期间NIHSS改善均优于未使用组。
- 大动脉粥样硬化型ΔNIHSS差异为-0.46(95%CI -0.75~-0.16)。
- 差异均小于1分NIHSS,临床意义有限。
核心结论
- 任何缺血性卒中亚型中,依达拉奉使用与神经症状更大改善相关,但差异小于1分NIHSS且临床意义有限。
研究设计与样本
- 研究纳入日本卒中数据银行2001年6月至2013年7月登记的61 048例18岁以上急性缺血性卒中患者,为医院为基础的多中心登记数据库。
- 按卒中亚型分层后分为依达拉奉组和未使用依达拉奉组,采用多变量线性回归及逆概率治疗加权分析。
主要发现
- 校正混杂因素后,大动脉粥样硬化型ΔNIHSS差异为-0.46(95%CI -0.75~-0.16)。
- 心源性栓塞型ΔNIHSS差异为-0.64(95%CI -1.09~-0.2)。
- 小血管闭塞型ΔNIHSS差异为-0.25(95%CI -0.4~-0.09)。
关键数值与推荐
- 主要结局为住院期间神经症状变化,即ΔNIHSS=出院时NIHSS评分-入院时NIHSS评分。
- 校正因素包括年龄、性别、治疗开始时收缩压和舒张压、入院NIHSS评分、发病至入院时间、梗死体积、合并症、合并用药等。
临床怎么用
- 真实世界中依达拉奉与各亚型缺血性卒中神经症状轻度改善相关,但改善幅度小于1分NIHSS,临床意义有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment. The purpose of this study was to assess the effect of edaravone on neurological symptoms in patients with ischemic stroke stratified by stroke subtype. Methods- Study subjects were 61 048 patients aged 18 years or older who were hospitalized ≤14 days after onset of an acute ischemic stroke and were registered in the Japan Stroke Data Bank, a hospital-based multicenter stroke registration database, between June 2001 and July 2013. Patients were stratified according to ischemic stroke subtype (large-artery atherosclerosis, cardioembolism, small-vessel occlusion, and cryptogenic/undetermined) and then divided into 2 groups (edaravone-treated and no edaravone). Neurological symptoms were evaluated using the National Institutes of Health Stroke Scale (NIHSS). The primary outcome was changed in neurological symptoms during the hospital stay (ΔNIHSS=NIHSS score at discharge-NIHSS score at admission). Data were analyzed using multivariate linear regression with inverse probability of treatment weighting after adjusting for the following confounding factors: age, gender, and systolic and diastolic blood pressure at the start of treatment, NIHSS score at admission, time from stroke onset to hospital admission, infarct size, comorbidities, concomitant medication, clinical department, history of smoking, alcohol consumption, and history of stroke. Results- After adjusting for potential confounders, the improvement in NIHSS score from admission to discharge was greater in the edaravone-treated group than in the no edaravone group for all ischemic stroke subtypes (mean [95% CI] difference in ΔNIHSS: -0.46 [-0.75 to -0.16] for large-artery atherosclerosis, -0.64 [-1.09 to -0.2] for cardioembolism, and -0.25 [-0.4 to -0.09] for small-vessel occlusion). Conclusions- For any ischemic stroke subtype, edaravone use (compared with no use) was associated with a greater improvement in neurological symptoms, although the difference was small (<1 point NIHSS) and of limited clinical significance.
引用
- Kobayashi S, Fukuma S, Ikenoue T, et al. Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. Stroke. 2019. PMID: 31164072. doi:10.1161/STROKEAHA.118.024351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。